Der Schweizer Pharmariese greift tief in die Tasche und kauft das auf Leberkrankheiten spezialisierte US-Biotech-Unternehmen 89bio.

Roche said on Thursday it agreed to acquire U.S. biotech firm 89bio ETNB.O for up to $3.5 billion to strengthen its development pipeline on liver and cardiometabolic disease treatments.

ExxonMobil shelves plastics recycling projects, NewMarket buys a hydrazine business, Roche to buy 89Bio in an up-to-$3.5 billion deal, and more

Roche will acquire 89bio in a deal worth up to $3.5B, gaining access to a late-stage MASH drug and strengthening its push into the obesity and metabolic disease market.

Roche to acquire 89bio for $2.4B, gaining pegozafermin, a late-stage fatty liver disease drug. Deal could reach $3.5B with contingent value rights.

Roche acquired 89bio for $2.4B after multiple increased offers and no competing bids. Deal included exploring pegozafermin for MASH and followed 2 years of discussions.

Roche acquired 89bio for $2.4B after multiple increased offers and no competing bids. Deal included exploring pegozafermin for MASH and followed 2 years of discussions.

Roche acquires 89bio in a $3.5B deal, adding a late-stage MASH therapy and expanding its focus on cardiovascular and metabolic diseases.

La farmacéutica Roche comprará biofarmacéutica de EEUU Por Redacción de Sin Comillas La farmacéutica suiza Roche ha llegado a un acuerdo para adquirir con la biofarmacéutica norteamericana 89bio,...

Using AI to find stock market opportunities. Click to read StockQuakes, by StockQuakes Team, a Substack publication with hundreds of subscribers.

Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share  Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet...

Newleos Therapeutics, a clinical-stage biotech focused on neuropsychiatric disorders, appointed Rohan Palekar to its Board of Directors and elected him Chairman. Christoph Westphal, who has served as Executive Chairman since Newleos’ founding, will step down from that role but remain on the Board representing founding investor Longwood Fund.According to Newleos, Palekar brings over 30 years of biotechnology and pharmaceutical experience, including serving as founding CEO of 89bio, where he led multiple programs from preclinical through Phase 3 in liver and cardiometabolic diseases; 89bio was acquired by Roche in 2025 for up to $3.5 billion. He previously was President and CEO of Avanir Pharmaceuticals, which was acquired by Otsuka Pharmaceutical in 2015, and Chief Commercial Officer at Medivation, after senior roles at Johnson & Johnson. Newleos highlights his CNS and company-building background as it approaches key clinical inflection points in ongoing anxiety trials. Palekar also serves on the board of Neurogene (Nasdaq: NGNE) and previously served on Neoleukin Therapeutics’ board.

Principaux renseignements Le géant pharmaceutique suisse Roche acquiert la société biotechnologique américaine 89bio pour 2,4 milliards de dollars (2,2 milliards d’euros), avec un potentiel pouvant atteindre 3,5 milliards de dollars (3,2 milliards d’euros) grâce à des paiements supplémentaires liés à des jalons. Cette acquisition vise à renforcer les efforts de recherche et développement de Roche […]

Die 89bio-Aktie (ISIN US28252C1099) steht nach der jüngsten Unternehmensübernahme im Fokus, denn für jede ETNB-Aktie wurde ein fester Barbetrag von 14,50 US-Dollar sowie eine zusätzliche Aktie des neuen Unternehmens gewährt, wie aus einem Corporate-Action-Hinweis per 28.08.2026 hervorgeht. Übernahmebedingungen und Bewertungsniveau Laut einem aktuellen Corporate-Action-Tracker erhalten frühere Anteilseigner von 89bio je gehaltene ETNB-Aktie 14,50 US-Dollar in bar und eine neue Aktie der Nachfolgegesellschaft; dieser Paketpreis bildet de facto den Bewertungsanker für die 89bio-Aktie am 28.08.2026.

スイスの製薬大手ロシュは、肝臓・心臓代謝疾患治療薬の開発を手掛ける米バイオテクノロジー企業８９ｂｉｏを買収することで合意したと１８日発表した。買収額は約２４億ドルで、偶発的価値の権利を含めると最大３５億ドルになるという。

スイスの製薬大手ロシュは、肝臓・心臓代謝疾患治療薬の開発を手掛ける米バイオテクノロジー企業８９ｂｉｏを買収することで合意したと１８日発表した。買収額は約２４億ドルで、偶発的価値の権利を含めると最大３５億ドルになるという。

スイスの製薬大手ロシュは、肝臓・心臓代謝疾患治療薬の開発を手掛ける米バイオテクノロジー企業８９ｂｉｏを買収することで合意したと１８日発表した。買収額は約２４億ドルで、偶発的価値の権利を含めると最大３５億ドルになるという。